Claims
- 1. A carbamate of 2-haloergoline or 2-haloergolene, having the formula: ##STR82## wherein R, R.sub.A, x y, Hal are defined as follows: ##STR83## wherein R.sub.1 and R.sub.2 independently represent (i) H, C.sub.1 -C.sub.8 straight alkyls, or C.sub.1 -C.sub.8 branched alkyls; C.sub.3 -C.sub.12 alicyclic groups; phenyl, benzyl, phenethyl, phenethyl substituted by an alkyl group, a dioxymethylene group, hydroxyl, or halogen; or R.sub.1 and R.sub.2 are connected to each other in the form: ##STR84## to form (ii) a C.sub.3 -C.sub.7 cyclic or bicyclic ring structure (iii) a heterocyclic ring structure of the formula: ##STR85## wherein Z represents an oxygen atom or the group N--R.sub.3, wherein R.sub.3 is H, or alkyl, and n is 2;
- (b) R is H, C.sub.1 -C.sub.5 straight alkyl or C.sub.1 -C.sub.5 branched alkyl;
- (c) x y represents --CH.sub.2 --CH< or --CH.dbd.C<; and
- (d) Hal is Cl, Br or I.
- 2. D-2-bromo-6-methyl-8beta-(N,N-dimethylcarbamoyloxymethyl)-9,10-didehydroergoline, according to the claim 1.
- 3. D-2-bromo-6-methyl-8beta-(perhydroazepinylcarbonyloxymethyl)-ergoline, according to the claim 1.
- 4. D-2-chloro-6-methyl-8beta-(perhydroazepinylcarbonyloxymethyl)-ergoline, according to claim 1.
- 5. D-2-bromo-6-methyl-8beta-(N,N-dimethylcarbamoyloxymethyl)ergoline, according to claim 1.
- 6. D-2-bromo-6-methyl-8beta-(N,N-diethylcarbamoyloxymethyl)-9,10-didehydroergoline, according to claim 1.
- 7. D-2-bromo-6-methyl-8beta-(N,N-diethylcarbamoyloxymethyl)-ergoline, according to claim 1.
- 8. D-2-bromo-6-methyl-8beta-(azetidinylcarbonyloxymethyl)-ergoline, according to claim 1.
- 9. D-2-bromo-6-methyl-8beta-pyrrolydylcarbonyloxymethyl)-9,10-didehydroergoline, according to claim 1.
- 10. D-2-bromo-6-methyl-8beta-(pyrrolydylcarbonyloxymethyl)-ergoline, according to claim 1.
- 11. D-2-bromo-6-methyl-8beta-(piperidinecarbonyloxymethyl)-9,10-didehydroergoline, according to claim 1.
- 12. D-2-bromo-6-methyl-8beta-(piperidinocarbonyloxymethyl)-ergoline, according to claim 1.
- 13. D-2-bromo-6-methyl-8beta-(perhydroazepinylcarbonyloxymethyl)-9,10-didehydroergoline, according to claim 1.
- 14. D-2-bromo-1,6-dimethyl-8beta-(perhydroazepinylcarbonyloxymethyl)-ergoline, according to claim 1.
- 15. D-2-iodo-6-methyl-8beta-(perhydroazepinylcarbonyloxymethyl)-ergoline, according to claim 1.
- 16. D-2-bromo-6-methyl-8beta-(morpholinocarbonyloxymethyl)-ergoline, according to claim 1.
- 17. D-2-bromo-1,6-dimethyl-8beta-(morpholinocarbonyloxymethyl)-ergoline, according to claim 1.
- 18. D-2-bromo-6-methyl-8beta-(4-methylpiperazinylcarbonyloxymethyl)-ergoline, according to claim 1.
- 19. D-2-bromo-6-methyl-8beta-(3-azabicyclo[3,2,2]nonanylcarbonyloxymethyl)-ergoline, according to claim 1.
- 20. D-2-bromo-6-methyl-8beta-(2-phenylisopropylcarbamoyloxymethyl)-9,10-didehydroergoline, according to claim 1.
- 21. A carbamate of 2-haloergoline or 2-haloergolene, having the formula: ##STR86## wherein R.sub.A represents the group: ##STR87## in which R.sub.1 and R.sub.2 independently represent H, C.sub.1 -C.sub.8 straight alkyl, C.sub.1 -C.sub.8 branched alkyl, phenyl, benzyl, or phenethyl, or R.sub.1 and R.sub.2 are connected to each other in the form: ##STR88## to form a piperidino, hexamethylenimino, azabicyclo [3,2,2-] nonane group: R is H, C.sub.1 -C.sub.5 straight alkyl, or C.sub.1 -C.sub.5 branched alkyl;
- x y represents --CH.sub.2 --CH< in both the possible stereoisomeric configurations, or --CH.dbd.C<; and
- Hal is chlorine, bromine or iodine.
- 22. A pharmaceutical composition for use as cerebral and peripheral vaso-dilator, as anti-hypertensive and in the therapy of cerebral arteriosclerosis, containing as the active ingredient a compound according to claim 1 and a pharmaceutically acceptable carrier therefor.
- 23. A pharmaceutical composition for the treatment of disorders of psychogenetic nature, containing, as the active ingredient, D-2-bromo-1,6-dimethyl-8beta-(perhydroazepinylcarbonyloxymethyl)-ergoline or a nontoxic pharmcologically acceptable salt thereof with an inorganic or organic acid along with an appropriate pharmacologically acceptable pharmaceutical carrier.
- 24. A pharmaceutical composition according to claim 23, wherein said compound is present in an amount comprised between 0.1 mg and 25 mg per dosage unit.
- 25. Pharmaceutical compositions for the treatment of asthma, containing, as the active ingredient, D-2-bromo-6-methyl-8beta-(morpholinocarbonyloxymethyl)-ergoline or a nontoxic pharmacologically acceptable salt thereof with an organic or inorganic acid, along with an appropriate pharmaceutically acceptable pharmaceutical carrier.
Priority Claims (1)
Number |
Date |
Country |
Kind |
3273/75 |
Mar 1975 |
CHX |
|
Parent Case Info
This is a continuation-in-part application of our U.S. Ser. No. 666,171 filed on Mar. 12, 1976, now abandoned.
US Referenced Citations (10)
Foreign Referenced Citations (1)
Number |
Date |
Country |
625559 |
Aug 1948 |
GBX |
Non-Patent Literature Citations (1)
Entry |
Troxler et al., Helv. Chim. Acta vol. 40, pp. 2160-2170 (1957). |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
666171 |
Mar 1976 |
|